GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

Biogend Therapeutics Co 6733.TWO · TWD

Health Care · Taipei Exchange · 🇹🇼 Taiwan

Compare

21.00

0.00%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Biogend Therapeutics Co

Its shares trade on Taipei Exchange under the ticker 6733.TWO. It has been listed since 18 June 2019. In the fiscal year to 31 December 2025, it reported revenue of TWD 222.3m and a net loss of TWD 84.6m. At that date it held total assets of TWD 815.4m and shareholders' equity of TWD 742.1m.

BioGend Therapeutics Co., Ltd. engages in the development of medical equipment to restore bone and joint functions. The company is headquartered in Taipei City, Taipei. The company went IPO on 2019-06-18. The firm is mainly engaged in the development and research of high-grade bone filling materials and knee cartilage repair related medical equipment. The firm's main products are BiG-001 which used for long bone biological aggregate, BiG-006 that used for lumbar interbody fusion biological bone, as well as BiG-009.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
18 Jun 2019

Leadership

Pay as last reported

  • Mr. Deli ChenChairman of the Board, General Manager, since 2022
  • Ms. Liangyan WangManager of Finance & Accounting
  • Ms. Jialing XiaoDeputy General Manager-Research & Development 1st Division
  • Shuwei ZhaoCorporate Governance Officer
  • Mr. Rongjin LinDirector, since 2016
  • Ms. Su-Chi WangDirector, since 2022
  • Hui-Heng HsuIndependent Director
  • Yu-Sheng LinIndependent Director
  • Mr. Hou ZengIndependent Director
  • Feng-Yee ZhangIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • BiG-001 for long bone biological aggregate development in Health Care sector
  • BiG-006 for lumbar interbody fusion biological bone in Health Care sector
  • BiG-009 for knee cartilage repair medical equipment in Health Care sector

Weaknesses

  • Biogend Therapeutics Co Ltd headquartered in Taipei City, Taiwan
  • Biogend Therapeutics Co Ltd listed on 18 June 2019
  • Biogend Therapeutics Co Ltd operates in Health Care sector

Opportunities

  • BiG-001 development for long bone biological aggregate in Taiwan market
  • BiG-006 development for lumbar interbody fusion biological bone in Taiwan market
  • BiG-009 development for knee cartilage repair in Taiwan market

Threats

  • Biogend Therapeutics Co Ltd faces competition in Health Care sector
  • Biogend Therapeutics Co Ltd faces regulatory challenges in Taiwan
  • Biogend Therapeutics Co Ltd faces market saturation in Health Care

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.